Lexaria Bioscience Advances Antiviral Research Initiative Using DehydraTECH™

Global innovator in drug delivery notches major deal with Boldt Runners Corporation

Lexaria Bioscience (OTC: LXRP; CSE: LXX) has formed a research and development framework agreement with British American Tobacco Limited (NYSE: BTI) to investigate Lexaria’s DehydraTECH technology for potential use in nicotine products, pairing Lexaria with an $81B global tobacco and consumer goods company.

The company also announced an expansion of its DehydraTECH platform to support its licensees, including Boldt Runners Corporation, and its Cannadips CBD product line. In its DehydraTECH CBD-processing division, Lexaria expects to produce over 4 million doses of CBD before Christmas.  Lexaria has received verbal notifications from existing licensed corporate clients to prepare to produce at least 56 million additional CBD servings during the calendar year 2021. These orders compare to roughly 700,000 servings processed in the quarter ending May 31, 2020.

Video Link: https://www.youtube.com/embed/oNUJeOo83EU

DehydraTECH technology results in a fast-acting, less expensive and more effective oral drug delivery by changing how active ingredients enter the bloodstream after oral intake, potentially providing vital benefits to antiviral drug administration and enhancing the drugs’ delivery properties. The platform has broad applications and is proven as a safe and effective method to deliver a more therapeutic drug absorption process. 

Assessments show effectiveness with a range of compounds including cannabinoids, vitamins, non-steroidal anti-inflammatory drugs (NSAIDs such as ibuprofen), nicotine and other molecules. The platform increases bio-absorption in the human bloodstream, reduces the time of onset and masks unwanted tastes for orally administered lipophilic drugs. The technology is also well-protected by 17 issued, and more than 60 patents pending, worldwide.

Updating a spring release that introduced an antiviral research initiative, Lexaria plans to conduct a pilot pharmacokinetic exploratory study in humans. Lexaria recently received conditional ethics board approval for this study as a an exploratory pharmacokinetic study in healthy volunteers to evaluate antiviral drugs previously studied and shown to have some effectiveness against other coronavirus strains.

In parallel with the pilot study, Lexaria announced the launch of a separate rodent antiviral study to evaluate pharmacokinetic benefits from the use of DehydraTECH in the delivery of representative drugs from two antiviral drug classes currently being assessed for their effectiveness against COVID-19. Study results are expected in December, and this data is expected to be an important predictor of whether DehydraTECH is capable of delivering higher proportionate doses of certain antiviral drugs of interest if DehydraTECH were incorporated compared to generic versions of those drugs.

Lexaria is leveraging the strength of DehydraTECH toward the fight against COVID-19 as well as other viruses that are likely to be investigated in the future. The company, however, is not making any express or implied claims that its product can eliminate, cure or contain the Covid-19 (or SARS-2) coronavirus at this time.

If Lexaria’s technology is proven to increase the delivery and effectiveness of antiviral drugs, the company can make its technology available to researchers worldwide to maximize drug effectiveness.

Find out more at https://get.ceo3in60.com/lxrp/


This communication was produced by PCG Digital Holdings, LLC, and affiliate of PCG Advisory Inc., (together “PCG”). PCG is an integrated investor relations, communications and strategic advisory firm. The information contained on this may be ‘Paid Advertising’ for purposes of Section 17(b) of the Securities Act of 1933, as amended (together with the rules and regulations there under, the “Securities Act”). PCG may be compensated by respective clients for publicizing information relating to its client’s securities. For more information in terms of compensation received for services provided by PCG, see the pertinent advertising materials relating to the respective client. By accessing this Site and any pages thereof, you agree to be bound by the Terms of Use and Privacy Policy.

PCG is not a registered or licensed broker, dealer, broker-dealer, investment adviser nor investment manager, nor does PCG engage in any activities that would require such registrations. PCG does not provide investment advice, endorsement, analysis or recommendations with respect to any securities, and its services to or statements about its clients should never be construed as any endorsement of or opinion about any security of any client.  No information contained in this communication constitutes an offer to sell, a solicitation of an offer to buy, or a recommendation of any security or any other similar product or service regardless of whether such security, product, or service is referenced in this communication. Further, nothing in this communication is intended to provide tax, legal, or investment advice and nothing in this communication should be construed as a recommendation to buy, sell or hold any investment or security or to engage in any investment strategy or transaction. For full disclaimers, including compensation received for professional services, please visit www.pcgadvisory.com/disclosures

Media Contact
Company Name: Prism Newswire
Contact Person: Ken Ellis
Email: [email protected]
Phone: 3057806988
Address:1118 N. Armour Street
City: Wichita
State: Kansas
Country: United States
Website: https://investorsprism.com